DNA and RNA of both natural and synthetic origin can elicit strong immune responses in higher organisms. Computer-aided design in conjunction with high-throughput sequencing has improved our ability to build tuneable synthetic DNA and RNA architectures with high structural and functional precision. The natural biological roles of nucleic acids endow these synthetic assemblies with the ability to specifically engage cellular components. This makes DNA and RNA particularly powerful materials with which to probe or programme immune cells. In this Perspective, we discuss the potential of designer nucleic acid assemblies to control and modulate the immune response for biomedical applications.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Rothemund, P. W. K. Folding DNA to create nanoscale shapes and patterns. Nature 440, 297–302 (2006).
Douglas, S. M. et al. Self-assembly of DNA into nanoscale three-dimensional shapes. Nature 459, 414–418 (2009).
Bhatia, D. et al. Quantum dot-loaded monofunctionalized DNA icosahedra for single-particle tracking of endocytic pathways. Nat. Nanotechnol. 11, 1112–1119 (2016).
Lee, H. et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat. Nanotechnol. 7, 389–393 (2012).
Krishnan, Y. & Bathe, M. Designer nucleic acids to probe and program the cell. Trends Cell Biol. 22, 624–633 (2012).
Paludan, S. R. & Bowie, A. G. Immune sensing of DNA. Immunity 38, 870–880 (2013).
Surana, S., Shenoy, A. R. & Krishnan, Y. Designing DNA nanodevices for compatibility with the immune system of higher organisms. Nat. Nanotechnol. 10, 741–747 (2015).
Khalil, D. N., Smith, E. L., Brentjens, R. J. & Wolchok, J. D. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 13, 273–290 (2016).
DeFrancesco, L. Landmark approval for Dendreon’s cancer vaccine. Nat. Biotechnol. 28, 531–532 (2010).
Shaughnessy, A. F. Monoclonal antibodies: magic bullets with a hefty price tag. BMJ 345, e8346 (2012).
Shang, N. et al. Dendritic cells based immunotherapy. Am. J. Cancer Res. 7, 2091–2102 (2017).
Oldenburg, M. et al. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science 337, 1111–1115 (2012).
Bauer, S. et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl Acad. Sci. USA 98, 9237–9242 (2001).
Ballas, Z. K. et al. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167, 4878–4886 (2001).
Chakraborty, K., Veetil, A. T., Jaffrey, S. R. & Krishnan, Y. Nucleic acid-based nanodevices in biological imaging. Annu. Rev. Biochem. 85, 349–373 (2016).
Rusconi, C. P. et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419, 90–94 (2002).
Groff, K., Brown, J. & Clippinger, A. J. Modern affinity reagents: recombinant antibodies and aptamers. Biotechnol. Adv. 33, 1787–1798 (2015).
Ruckman, J. et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273, 20556–20567 (1998).
Rohloff, J. C. et al. Nucleic acid ligands with protein-like side chains: modified aptamers and their use as diagnostic and therapeutic agents. Mol. Ther. Nucleic Acids 3, e201 (2014).
Klussmann, S., Nolte, A., Bald, R., Erdmann, V. A. & Fürste, J. P. Mirror-image RNA that binds D-adenosine. Nat. Biotechnol. 14, 1112–1115 (1996).
Pastor, F. et al. An RNA toolbox for cancer immunotherapy. Nat. Rev. Drug Discov. 17, 751–767 (2018).
Chaplin, D. D. Overview of the immune response. J. Allergy Clin. Immunol. 125, S3–23 (2010).
Arazi, A., Pendergraft, W. F., Ribeiro, R. M., Perelson, A. S. & Hacohen, N. Human systems immunology: hypothesis-based modeling and unbiased data-driven approaches. Semin. Immunol. 25, 193–200 (2013).
Wang, X. et al. Three-dimensional intact-tissue sequencing of single-cell transcriptional states. Science 361, eaat5691 (2018).
Chen, K. H., Boettiger, A. N., Moffitt, J. R., Wang, S. & Zhuang, X. RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells. Science 348, aaa6090 (2015).
Iyengar, R. Why we need quantitative dynamic models. Sci. Signal. 2, eg3 (2009).
Jungmann, R. et al. Single-molecule kinetics and super-resolution microscopy by fluorescence imaging of transient binding on DNA origami. Nano Lett. 10, 4756–4761 (2010).
Jungmann, R. et al. Quantitative super-resolution imaging with qPAINT. Nat. Methods 13, 439–442 (2016).
Strauss, S. et al. Modified aptamers enable quantitative sub-10-nm cellular DNA-PAINT imaging. Nat. Methods 15, 685–688 (2018).
Satija, R. & Shalek, A. K. Heterogeneity in immune responses: from populations to single cells. Trends Immunol. 35, 219–229 (2014).
Avraham, R. et al. Pathogen cell-to-cell variability drives heterogeneity in host immune responses. Cell 162, 1309–1321 (2015).
Prakash, V. et al. Quantitative maps of endosomal DNA processing by single molecule counting. Angew. Chem. Int. Ed Engl. 58, 3073–3076 (2019).
Domenyuk, V. et al. Plasma exosome profiling of cancer patients by a next generation systems biology approach. Sci. Rep. 7, 42741 (2017).
Domenyuk, V. et al. Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. Nat. Commun. 9, 1219 (2018).
Dan, K., Veetil, A. T., Chakraborty, K. & Krishnan, Y. DNA nanodevices map enzymatic activity in organelles. Nat. Nanotechnol. 14, 252–259 (2019).
Thekkan, S. et al. A DNA-based fluorescent reporter maps HOCl production in the maturing phagosome. Nat. Chem. Biol. https://doi.org/10.1038/s41589-018-0176-3 (2018).
Surana, S., Bhat, J. M., Koushika, S. P. & Krishnan, Y. An autonomous DNA nanomachine maps spatiotemporal pH changes in a multicellular living organism. Nat. Commun. 2, 340 (2011).
Modi, S. et al. A DNA nanomachine that maps spatial and temporal pH changes inside living cells. Nat. Nanotechnol. 4, 325–330 (2009).
Kawasaki, T. & Kawai, T. Toll-like receptor signaling pathways. Front. Immunol. 5, 461 (2014).
Bogdan, C. Nitric oxide and the immune response. Nat. Immunol. 2, 907–916 (2001).
Tan, R. S. T., Ho, B., Leung, B. P. & Ding, J. L. TLR cross-talk confers specificity to innate immunity. Int. Rev. Immunol. 33, 443–453 (2014).
Jayasena, S. D. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin. Chem. 45, 1628–1650 (1999).
Ellington, A. D. & Szostak, J. W. In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818–822 (1990).
Tuerk, C. & Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505–510 (1990).
Alam, K. K., Chang, J. L. & Burke, D. H. FASTAptamer: a bioinformatic toolkit for high-throughput sequence analysis of combinatorial selections. Mol. Ther. Nucleic Acids 4, e230 (2015).
Cho, M. et al. Quantitative selection of DNA aptamers through microfluidic selection and high-throughput sequencing. Proc. Natl Acad. Sci. USA 107, 15373–15378 (2010).
Soldevilla, M. M., Villanueva, H. & Pastor, F. Aptamers: a feasible technology in cancer immunotherapy. J. Immunol. Res. 2016, 1083738 (2016).
Sun, H. et al. Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol. Ther. Nucleic Acids 3, e182 (2014).
Moynihan, K. D. & Irvine, D. J. Roles for innate immunity in combination immunotherapies. Cancer Res. 77, 5215–5221 (2017).
Gajewski, T. F., Schreiber, H. & Fu, Y.-X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014–1022 (2013).
Kärre, K., Ljunggren, H. G., Piontek, G. & Kiessling, R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319, 675–678 (1986).
Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
Curran, M. A., Montalvo, W., Yagita, H. & Allison, J. P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107, 4275–4280 (2010).
Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887–3895 (1992).
Buchbinder, E. I. & Desai, A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol. 39, 98–106 (2016).
Santulli-Marotto, S., Nair, S. K., Rusconi, C., Sullenger, B. & Gilboa, E. Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res. 63, 7483–7489 (2003).
Devaraj, S. G. T., Lokesh, G. L. R., Zu, Y., Chang, J. & Iyer, S. P. DNA aptamer against anti- programmed cell death-1 (Anti-PD1-Apt) induces robust anti-leukemic activity in vitro and in vivo humanized NSG mice with myeloid leukemia xenografts. Blood 130 (Suppl. 1), 1373 (2017).
Moore, K. W., de Waal Malefyt, R., Coffman, R. L. & O’Garra, A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19, 683–765 (2001).
Zheng, L. M. et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J. Exp. Med. 184, 579–584 (1996).
Berezhnoy, A. et al. Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing. Mol. Ther. 20, 1242–1250 (2012).
Lee, S.-W., Salek-Ardakani, S., Mittler, R. S. & Croft, M. Hypercostimulation through 4-1BB distorts homeostasis of immune cells. J. Immunol. 182, 6753–6762 (2009).
Pastor, F., Kolonias, D., McNamara, J. O. & Gilboa, E. Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. Mol. Ther. 19, 1878–1886 (2011).
Tsou, P., Katayama, H., Ostrin, E. J. & Hanash, S. M. The emerging role of B cells in tumor immunity. Cancer Res. 76, 5597–5601 (2016).
Von Bergwelt-Baildon, M. S. et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 99, 3319–3325 (2002).
Soldevilla, M. M. et al. 2-Fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia. Biomaterials 67, 274–285 (2015).
Raddatz, M.-S. L. et al. Enrichment of cell-targeting and population-specific aptamers by fluorescence-activated cell sorting. Angew. Chem. Int. Ed Engl. 47, 5190–5193 (2008).
Mayer, G. et al. Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures. Nat. Protoc. 5, 1993–2004 (2010).
Opazo, F. et al. Modular assembly of cell-targeting devices based on an uncommon G-quadruplex aptamer. Mol. Ther. Nucleic Acids 4, e251 (2015).
Thompson, J. S. et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293, 2108–2111 (2001).
Zhou, J. et al. Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells. Nucleic Acids Res. 41, 4266–4283 (2013).
Datta, S. K. Production of pathogenic antibodies: cognate interactions between autoimmune T and B cells. Lupus 7, 591–596 (1998).
Hardy, I. R. et al. Anti-CD79 antibody induces B cell anergy that protects against autoimmunity. J. Immunol. 192, 1641–1650 (2014).
Dörner, T. et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. 8, R74 (2006).
Palucka, K. & Banchereau, J. Dendritic cells: a link between innate and adaptive immunity. J. Clin. Immunol. 19, 12–25 (1999).
Sallusto, F. & Lanzavecchia, A. The instructive role of dendritic cells on T cell responses. Arthritis Res. 4, (Suppl. 3), S127–S132 (2002).
De Saint-Vis, B. et al. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J. Immunol. 160, 1666–1676 (1998).
Blanco, P., Palucka, A. K., Pascual, V. & Banchereau, J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 19, 41–52 (2008).
Lai, Y. & Dong, C. Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. Int. Immunol. 28, 181–188 (2016).
Boshtam, M., Asgary, S., Kouhpayeh, S., Shariati, L. & Khanahmad, H. Aptamers against pro- and anti-inflammatory cytokines: a review. Inflammation 40, 340–349 (2017).
Takai, T., Li, M., Sylvestre, D., Clynes, R. & Ravetch, J. V. FcR γ chain deletion results in pleiotrophic effector cell defects. Cell 76, 519–529 (1994).
Nathan, C. F., Murray, H. W. & Cohn, Z. A. The macrophage as an effector cell. N. Engl. J. Med. 303, 622–626 (1980).
Desjarlais, J. R., Lazar, G. A., Zhukovsky, E. A. & Chu, S. Y. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer’s perspective. Drug Discov. Today 12, 898–910 (2007).
Boltz, A. et al. Bi-specific aptamers mediating tumor cell lysis. J. Biol. Chem. 286, 21896–21905 (2011).
Hsi, E. D. et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin. Cancer Res. 14, 2775–2784 (2008).
Thielens, A., Vivier, E. & Romagné, F. NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr. Opin. Immunol. 24, 239–245 (2012).
Kohrt, H. E. et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123, 678–686 (2014).
Godal, R. et al. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. Biol. Blood Marrow Transplant. 16, 612–621 (2010).
Cohen, R. et al. Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): preliminary assessment of safety and efficacy [abstract]. Cancer Res. 78, (Suppl. 13), CT158 (2018).
Cassetta, L. & Kitamura, T. Macrophage targeting: opening new possibilities for cancer immunotherapy. Immunology 155, 285–293 (2018).
Brown, J. M., Recht, L. & Strober, S. The promise of targeting macrophages in cancer therapy. Clin. Cancer Res. 23, 3241–3250 (2017).
Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889–896 (2010).
Georgoudaki, A.-M. et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. 15, 2000–2011 (2016).
Hume, D. A. & MacDonald, K. P. A. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119, 1810–1820 (2012).
Ries, C. H. et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25, 846–859 (2014).
Cannarile, M. A. et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J. Immunother. Cancer 5, 53 (2017).
Fujioka, Y. et al. A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion. Mol. Cell. Biol. 16, 6887–6899 (1996).
Ring, N. G. et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc. Natl Acad. Sci. USA 114, E10578–E10585 (2017).
Wang, R. et al. Automated modular synthesis of aptamer-drug conjugates for targeted drug delivery. J. Am. Chem. Soc. 136, 2731–2734 (2014).
Alley, S. C., Okeley, N. M. & Senter, P. D. Antibody-drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 14, 529–537 (2010).
Diamantis, N. & Banerji, U. Antibody-drug conjugates—an emerging class of cancer treatment. Br. J. Cancer 114, 362–367 (2016).
Sassoon, I. & Blanc, V. Antibody-drug conjugate (ADC) clinical pipeline: a review. Methods Mol. Biol. 1045, 1–27 (2013).
Ohta, A. & Sitkovsky, M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916–920 (2001).
De Lera Ruiz, M., Lim, Y.-H. & Zheng, J. Adenosine A2A receptor as a drug discovery target. J. Med. Chem. 57, 3623–3650 (2014).
Chiang, M.-J. et al. An Fc domain protein-small molecule conjugate as an enhanced immunomodulator. J. Am. Chem. Soc. 136, 3370–3373 (2014).
Differding, E. AUNP-12 - a novel peptide therapeutic targeting PD-1 immune checkpoint pathway for cancer immunotherapy – structure activity relationships & peptide / peptidomimetic analogs. Differding.com http://www.differding.com/data/AUNP_12_A_novel_peptide_therapeutic_targeting_PD_1_immune_checkpoint_pathway_for_cancer_immunotherapy.pdf (2014).
Shimizu-Sato, S., Huq, E., Tepperman, J. M. & Quail, P. H. A light-switchable gene promoter system. Nat. Biotechnol. 20, 1041–1044 (2002).
Gossen, M. & Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl Acad. Sci. USA 89, 5547–5551 (1992).
Liang, J. C., Bloom, R. J. & Smolke, C. D. Engineering biological systems with synthetic RNA molecules. Mol. Cell 43, 915–926 (2011).
Vinkenborg, J. L., Karnowski, N. & Famulok, M. Aptamers for allosteric regulation. Nat. Chem. Biol. 7, 519–527 (2011).
Mandal, M. & Breaker, R. R. Gene regulation by riboswitches. Nat. Rev. Mol. Cell Biol. 5, 451–463 (2004).
Beisel, C. L., Chen, Y. Y., Culler, S. J., Hoff, K. G. & Smolke, C. D. Design of small molecule-responsive microRNAs based on structural requirements for Drosha processing. Nucleic Acids Res. 39, 2981–2994 (2011).
Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233 (2009).
An, C.-I., Trinh, V. B. & Yokobayashi, Y. Artificial control of gene expression in mammalian cells by modulating RNA interference through aptamer-small molecule interaction. RNA 12, 710–716 (2006).
Rosenberg, S. A. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192, 5451–5458 (2014).
Fyfe, G. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688–696 (1995).
Atkins, M. B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105–2116 (1999).
Kammula, U. S., White, D. E. & Rosenberg, S. A. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83, 797–805 (1998).
Dutcher, J. P. et al. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989–1997. Cancer J. Sci. Am. 3 (Suppl. 1), S73–S78 (1997).
Chen, Y. Y., Jensen, M. C. & Smolke, C. D. Genetic control of mammalian T cell proliferation with synthetic RNA regulatory systems. Proc. Natl Acad. Sci. USA 107, 8531–8536 (2010).
Ji, Y., Hocker, J. D. & Gattinoni, L. Enhancing adoptive T cell immunotherapy with microRNA therapeutics. Semin. Immunol. 28, 45–53 (2016).
The authors thank J. Kuriyan (University of California, Berkeley) and V. Kumar (The University of Chicago) for comments and suggestions. This work was supported by a research grant from the University of Pennsylvania Orphan Disease Center in partnership with the Andrew Coppola Foundation, the University of Chicago Women’s Board; a Pilot and Feasibility award from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Center grant no. P30DK42086 to the University of Chicago Digestive Diseases Research Core Center; the Chicago Biomedical Consortium, with support from the Searle Funds at The Chicago Community Trust, C-084; and University of Chicago start-up funds to Y.K. Y.K. is a Brain Research Foundation Fellow. Our sincere apologies to those colleagues whose work could not be included owing to space limitations.
The authors declare no competing interests
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Jani, M.S., Veetil, A.T. & Krishnan, Y. Precision immunomodulation with synthetic nucleic acid technologies. Nat Rev Mater 4, 451–458 (2019). https://doi.org/10.1038/s41578-019-0105-4
Nature Reviews Materials (2021)
Nature Chemical Biology (2020)